Thermo Scientific QMS Everolimus Assay Kit receives CE Mark for liver transplant application

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its Thermo Scientific QMS Everolimus Assay Kit has been CE marked for sale in the European Union for a third application, namely liver transplants. This new indication allows laboratories to monitor blood levels of everolimus, the active ingredient in the drug Certican® (manufactured by Novartis Pharmaceuticals) in liver transplant patients. Previously, the QMS® Everolimus Assay Kit was CE marked for kidney and heart transplant applications. In the United States, the QMS Everolimus Assay Kit has U.S. Food and Drug Administration (FDA) clearance for use in monitoring kidney transplant patients. Thermo Fisher Scientific was the first company to offer a CE marked and FDA cleared assay for monitoring everolimus in kidney transplant patients.

The QMS® Everolimus Assay Kit rounds out Thermo Fisher Scientific's menu of immunoassays for immunosuppressant drugs including cyclosporine, tacrolimus, and mycophenolic acid.

Thermo Fisher Scientific has a proven track record for supplying high-quality reagents, calibrators and controls that dates back to 1989. The company's homogeneous immunoassay products have been used in many major clinical laboratories and drug testing facilities around the world. The ready-to-use, liquid QMS assays are used on automatic clinical chemistry analyzers as part of therapeutic drug monitoring, an integral part in organ transplant recipient treatment programs.

Thermo Scientific QMS Everolimus Calibrator and Control sets are also available for use with the QMS Everolimus Assay. The calibrator kit contains six different calibrators to complete a full six-point calibration as part of the test procedure; the QMS Everolimus Control Set contains three levels.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thermo Fisher Scientific Inc.. (2019, June 24). Thermo Scientific QMS Everolimus Assay Kit receives CE Mark for liver transplant application. News-Medical. Retrieved on October 10, 2024 from https://www.news-medical.net/news/20130116/Thermo-Scientific-QMS-Everolimus-Assay-Kit-receives-CE-Mark-for-liver-transplant-application.aspx.

  • MLA

    Thermo Fisher Scientific Inc.. "Thermo Scientific QMS Everolimus Assay Kit receives CE Mark for liver transplant application". News-Medical. 10 October 2024. <https://www.news-medical.net/news/20130116/Thermo-Scientific-QMS-Everolimus-Assay-Kit-receives-CE-Mark-for-liver-transplant-application.aspx>.

  • Chicago

    Thermo Fisher Scientific Inc.. "Thermo Scientific QMS Everolimus Assay Kit receives CE Mark for liver transplant application". News-Medical. https://www.news-medical.net/news/20130116/Thermo-Scientific-QMS-Everolimus-Assay-Kit-receives-CE-Mark-for-liver-transplant-application.aspx. (accessed October 10, 2024).

  • Harvard

    Thermo Fisher Scientific Inc.. 2019. Thermo Scientific QMS Everolimus Assay Kit receives CE Mark for liver transplant application. News-Medical, viewed 10 October 2024, https://www.news-medical.net/news/20130116/Thermo-Scientific-QMS-Everolimus-Assay-Kit-receives-CE-Mark-for-liver-transplant-application.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New developments at Evosep to make clinical proteomics 100x more robust and 10x faster